SLC5A2 and diabetes mellitus: SGLT2 inhibitor treatment results in dose-dependent improvements in measures of kidney function and inflammatory and oxidative stress in animal models of adenine-induced chronic kidney disease (16, 17) and leads to early decreases in kidney injury markers independently of albuminuria in individuals with diabetes.